Ashwagandha’s two-sided record: limited evidence and liver-injury cases

Two findings in one entry

Of the six names on this label, ashwagandha is the one with the most attached to it in our sources, and what is attached runs in two directions at once. It has the closest thing here to support for the claim the product is sold on. It also has the clearest safety signal on the label.

Both come from the same page, the NCCIH entry on ashwagandha, and a reader who takes one half and leaves the other is not reading the source. This post takes both.

One boundary before starting. Nothing on this page is about Alpha Erec specifically. No published human trial on the finished formula exists in anything we have read, and our sources describe the ingredient rather than the gummy. With no amount published for the ashwagandha in this product, the distance between the two is not measurable.

What NIH reports it may be effective for

Start with what the source reports on the positive side, in its own terms.

NIH says research shows some ashwagandha preparations may be effective for insomnia and stress. It says the evidence is unclear on anxiety. And it says there is limited evidence that it may increase testosterone levels and sperm quality over two to four months.

Read the qualifiers. Some preparations, not the plant in general: preparation is a quantity and a process question, and this label names neither. May be effective, which is a different verb from is. Unclear on anxiety, which is a real result and not a gap in the page.

Note also what the effective-for list contains: insomnia and stress. Neither is what this product is sold for. A gummy in the men's performance category carries ashwagandha for the third finding, and the third finding is the most heavily hedged of the three.

The liver-injury cases

Now the other half, and it gets the same space.

NIH says there have been a number of cases linking liver injury to ashwagandha supplements.

That is the sentence. This page is not going to enlarge it with numbers, severity or mechanisms our source does not give, and it is not going to shrink it either. A number of cases is a signal. It is not a claim that the ingredient injures most people who take it, and it is not a claim about this product, which nobody has tested.

What makes it matter more here than on a fully disclosed label is the missing amount. A person taking a second supplement containing ashwagandha cannot add up what they are taking, because one of the two numbers does not exist. Stacking is the ordinary way people end up with more of an ingredient than they intended, and an unquantified product is the one that makes stacking impossible to track.

The practical version: know that ashwagandha is in this gummy, tell a clinician you are taking it, and treat any new symptom as worth reporting rather than waiting out.

Short term, up to three months

The source adds a duration to the safety half as well: ashwagandha may be safe in the short term, up to three months.

Three months is 90 days, which is exactly the three-bottle pack. The six-bottle pack is 180 days, which is twice that duration. Nothing in our source says what happens beyond three months; it says the short-term statement covers up to three. Absence of a statement is not a finding of harm, and it is not a clearance either.

Hold the two durations together and the picture is unusual. The testosterone finding describes two to four months. The short-term safety statement covers up to three. The upper end of the first sits outside the second, which is a tension in the literature rather than something this site invented, and it is a reasonable thing to put to a clinician.

The label itself says: For healthy adults 18 and over only. Talk to a doctor before use if you take any medicine. Do not take more than the label says unless a clinician tells you to.